Navigation Links
Roche Receives FDA Approval for a Second-Generation Hepatitis C Viral Load Test
Date:10/25/2010

PLEASANTON, Calif., Oct. 25 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food & Drug Administration (FDA) has approved the real-time PCR COBAS® TaqMan® HCV Test, v2.0. Clinical research organizations have depended on COBAS® TaqMan® technology to support hepatitis C pharmaceutical trials and development. This new test will help clinicians to more confidently and effectively monitor their patients, and to improve treatment outcomes.

"This HCV quantitative test is key to measuring the effectiveness of many antivirals that are currently in clinical development for the treatment of hepatitis C," said Teresa Wright, M.D., Chief Medical Officer of Roche Molecular Diagnostics. "Roche is committed to providing complete diagnostic and treatment solutions for this important global disease."

About COBAS® TaqMan® HCV Test, v2.0 For Use With High Pure SystemDesigned for use with the High Pure System Viral Nucleic Acid Kit, the COBAS® TaqMan® HCV Test, v2.0 is intended to quantify the amount of hepatitis C viral RNA in human plasma or serum of HCV infected individuals. The test incorporates a manual specimen preparation and the COBAS® TaqMan® 48 Analyzer for automated amplification and detection. Roche now offers HCV viral load test for both automated and manual specimen preparation methods; further demonstrating Roche's commitment in providing workflow options and flexibilities for the diverse needs of laboratories. The test system benefits from the proven contamination controls designed into all COBAS® TaqMan® assays, including built-in Roche-proprietary AmpErase enzyme.

About Hepatitis CAccording to the Centers for Disease Control, Hepatitis C virus (HCV) infection is the most common chronic blood borne infection in the United States; approximately 3.2 million persons are chronically infected.

Each year in the U.S. approximately 8,000 – 10,000 people die from hepatitis C-related liver disease. An estimated 3.2 million persons in the United States have chronic hepatitis C virus infection. Most people do not know they are infected because they don't look or feel sick. However, approximately 75 – 85% of people who become infected with hepatitis C virus develop infection.(1)

Hepatitis C infections can range in severity from a mile of "acute" illness lasting a few weeks to a serious, lifelong or "chronic" illness. For most people, acute infection leads to chronic infection. Chronic hepatitis C infection is a serious disease that can result in long-term health problems, including liver damage, liver failure, liver cancer, or even death. Hepatitis C is the leading cause of cirrhosis and liver cancer and the most common reason for liver transplantation in the United States.

Hepatitis C virus is passed when infected blood enters the body of someone who is not infected. People can be infected by sharing contaminated needles, high risk sex with an infected partner, and from an infected mother to her infant during pregnancy and childbirth.

About RocheHeadquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80,000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

(1) U.S. Centers for Disease Control. http://www.cdc.gov

All trademarks used or mentioned in this release are legally protected by law.For further information please contact:Jacqueline WallachMolecular Diagnostics Communication925.730.8114
'/>"/>

SOURCE Roche
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Roche Acquires RALS IT Connectivity Assets to Strengthen Presence in Point-of-Care Information Management
2. Roche and German Cancer Research Center (DKFZ) Enter Research Agreement to Predict Cervical Cancer
3. Roche Diagnostics Supports Fight Against MRSA as a Sponsor of Annual World MRSA Day
4. Roche Receives FDA Approval for Second-Generation Hepatitis B Viral Load Test
5. AstraZeneca Joins Rochester Initiative to Further Cardiac Safety
6. Roche Launches New Initiative - Roche Goes to Town
7. Roche Diagnostics Introduces Full Line of 9-Minute STAT Assays for Cardiac Biomarker Testing on cobas 6000 Analyzer Series
8. Roche Receives FDA Clearance for U.S. Launch of cobas 8000 Modular Analyzer Series for High-Volume Laboratory Testing
9. New England Biolabs Launches NEBNext™ Quick DNA Sample Prep Reagent Sets for Use With Roche/454 Next Generation Sequencing Platforms
10. caprotec bioanalytics Announces the Successful Completion of a Collaborative Research Project With Roche
11. Rochester Medical Corporation Honored by Premier Healthcare Alliance for Exceptional Supplier Performance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... 2016   AlloSource , one of the ... and soft-tissue allografts for use in surgical procedures, ... for being named to the Board of Examiners ... by the Commerce Department,s National Institute of Standards ... process excellence. The Baldrige Award is the nation,s ...
(Date:12/6/2016)... Dec. 6, 2016 Eurofins Genomics today ... the College of American Pathologists (CAP) and certification ... its new laboratory in Louisville, KY ... North American headquarters. "Our new CLIA-licensed ... which is still considered the ,Gold Standard, method ...
(Date:12/6/2016)... 6, 2016  Nearly 30 million people in ... epidemic of diabetes. 1 However, nearly 40% of ... levels (hyperglycemia) and significant glucose variability. 2 These patients ... cardiovascular events. If left untreated, hyperglycemia can lead to ... or blindness. 3 As part of ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... 06, 2016 , ... An inventor, from Talladega, Ala., thought there needed to ... the patent-pending SLING-VEST. , The SLING-VEST provides an effective way to support and align ... slings. As a result, it helps to reduce discomfort and shifting. The invention features ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... ... (PHM) technology, has named Ajdin Camaga as a vice president of sales. , ... Justin Neece, president. “He works hard to understand what each client needs, and ...
(Date:12/6/2016)... TX (PRWEB) , ... December ... ... in predictive and prescriptive health insights for population health management, announces today ... provider. VitreosHealth will leverage CitiusTech’s cloud-hosted clinical rules engine that offers advanced ...
(Date:12/6/2016)... New York, NY (PRWEB) , ... December 06, 2016 , ... ... a collaboration led by the Department of Neurosurgery, where clinicians can confer and order ... be provided on a low-cost fee-for-service basis with quick turnaround times. This resource ...
(Date:12/6/2016)... , ... December 06, 2016 , ... ... at the Maine Women’s Magazine inaugural Maine Women’s Expo. Hundreds of women gathered ... an amazing local resource. The expo’s beneficiary this year was Crossroads, a fully-accredited ...
Breaking Medicine News(10 mins):